Dr. Glenn Egrie, MD

Cardiac Surgery  ·  
Male  ·  
Age 50
(1)
Insurances Accepted  ·  Save
Dr. Glenn Egrie, MD
Dr. Glenn Egrie, MD is a cardiac surgery specialist in San Francisco, CA and has been practicing for 23 years. He graduated from Mount Sinai School Of Medicine Of New York University in 1995 and specializes in cardiac surgery.

Risks associated with the TAVR procedure include death, stroke and major bleeding

Important Risk Information for Patients

Indications:

The Edwards SAPIEN 3 transcatheter heart valve, model 9600TFX, and accessories are indicated for relief of aortic stenosis in patients with symptomatic heart disease due to severe native calcific aortic stenosis who are judged by a Heart Team, including a cardiac surgeon, to be at intermediate or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 3% at 30 days, based on the Society of Thoracic Surgeons (STS) risk score and other clinical co-morbidities unmeasured by the STS risk calculator).

The Edwards SAPIEN 3 transcatheter heart valve, model 9600TFX, and accessories are indicated for patients with symptomatic heart disease due to failure (stenosed, insufficient, or combined) of a surgical bioprosthetic aortic or mitral valve who are judged by a heart team, including a cardiac surgeon, to be at high or greater risk for open surgical therapy (i.e., predicted risk of surgical mortality ≥ 8% at 30 days, based on the STS risk score and other clinical co-morbidities unmeasured by the STS risk calculator).

Contraindications (Who should not use):

The Edwards SAPIEN 3 transcatheter heart valve and delivery system should not be used in patients who:

  • Cannot tolerate medications that thin the blood or prevent blood clots from forming.
  • Have an active infection in the heart or elsewhere.

Warnings:

  • There may be an increased risk of stroke in transcatheter aortic valve replacement procedures, compared to other standard treatments for aortic stenosis in the high or greater risk population.
  • If an incorrect valve size for your anatomy is used, it may lead to heart injury, valve leakage, movement, or dislodgement.
  • Patients should talk to their doctor if they have significant heart disease, a mitral valve device or are allergic to chromium, nickel, molybdenum, manganese, copper, silicon, and/or polymeric materials.
  • The SAPIEN 3 valve may not last as long in patients whose bodies do not process calcium normally.
  • During the procedure, your doctors should monitor the dye used in the body; if used in excess it could lead to kidney damage. X-ray guidance used during the procedure may cause injury to the skin, which may be painful, damaging, and long-lasting.
  • Transcatheter aortic heart valve patients should take medications that thin the blood or prevent blood clots from forming, except when likely to have an adverse reaction, as determined by their physician. The Edwards SAPIEN 3 transcatheter heart valve has not been tested for use without medications that thin the blood or prevent blood clots from forming.

Precautions:

The long-term durability of the Edwards SAPIEN 3 transcatheter heart valve is not known at this time. Regular medical follow-up is recommended to evaluate how well a patient’s heart valve is performing. Safety, performance, and durability of the SAPIEN 3 valve has not been established for placement inside a previously implanted transcatheter valve.

The safety and effectiveness of the transcatheter heart valve is also not known for patients who have:

  • An aortic heart valve that is not calcified, contains only one or two leaflets, has leaflets with large pieces of calcium that may block the vessels that supply blood to the heart or in which the main problem is that the valve leaks.
  • Previous prosthetic ring in any position.
  • Previous atrial septal occlude.
  • A heart that does not pump well, has thickening of the heart muscle, with or without blockage, unusual ultrasound images of the heart that could represent irregularities such as a blood clot, a diseased mitral valve that is calcified or leaking, or Gorlin syndrome, a condition that affects many areas of the body and increases the risk of developing various cancers and tumors.
  • Low white, red or platelet blood cell counts, or history of bleeding because the blood does not clot properly.
  • Diseased, abnormal or irregularly shaped vessels leading to the heart. Vessels which are heavily diseased or too small for associated delivery devices, or a large amount of calcification at the point of entry.
  • Allergies to blood-thinning medications or dye injected during the procedure.
  • For a valve in valve procedure, there is a risk of leakage if the previously implanted tissue valve is not securely in place or if it is damaged. There is also the possibility that a partially detached valve leaflet from the previously implanted valve could block a blood vessel.
  • Additional pre-procedure imaging will be completed to evaluate proper sizing.

Potential risks associated with the procedure include:

  • Death, stroke, paralysis (loss of muscle function), permanent disability, or severe bleeding.
  • Risks to the heart, including heart attack or heart failure, a heart that does not pump well, irregular heartbeat that may result in a need for a permanent pacemaker, chest pain, heart murmur, false aneurysm, recurring aortic stenosis(narrowing), too much fluid around the heart, injury to the structure of the heart.
  • Risks to your lungs or breathing, including difficulty breathing, fainting, buildup of fluid in or around the lungs, weakness or inability to exercise.
  • Risks involving bleeding or your blood supply, including formation of a blood clot, high or low blood pressure, limited blood supply, a decrease in red blood cells, or abnormal lab values, bleeding in the abdominal cavity, collection of blood under the skin.
  • Additional risks, including life-threatening infection, dislodgement of calcified material, air embolism (air bubbles in the blood vessels), poor kidney function or failure, nerve injury, fever, allergic reaction to anesthesia or dye, reoperation, pain, infection or bleeding at incision sites, or swelling.

Additional potential risks specifically associated with the use of the heart valve include:

  • Valve movement after deployment, blockage or disruption of blood flow through the heart, need for additional heart surgery and possible removal of the SAPIEN 3 valve, a blood clot that requires treatment, damage to the valve (e.g., wear, breakage, recurring aortic stenosis), nonstructural valve dysfunction (e.g., leakage, inappropriate sizing or positioning, blockage, excess tissue in growth, blood cell damage, etc.) or mechanical failure of the delivery system and/or accessories.

CAUTION: Federal (United States) law restricts these devices to sale by or on the order of a physician.

Edwards, Edwards Lifesciences, the stylized E logo, Edwards SAPIEN, Edwards SAPIEN 3, SAPIEN, and SAPIEN 3 are trademarks of Edwards Lifesciences Corporation. All other trademarks are the property of their respective owners.

© 2017 Edwards Lifesciences Corporation. All rights reserved. PP--US-2507 v1.0

Edwards Lifesciences One Edwards Way, Irvine CA 92614 USA edwards.com

2340 Clay St

San Francisco, CA 94115

Contact Information

(415) 600-1386

Dr. Glenn Egrie, MD

Dr. Glenn Egrie, MD

Accepted insurance

  • Aetna
  • Blue Cross Blue Shield
  • Blue Cross Blue Shield of California
  • Cigna
  • MultiPlan

*Please verify this information when scheduling an appointment.

Background Check

No malpractice claims found for California
No disciplinary actions found for the years we collect data
No board actions found for the years we collect data
Learn more about background checks

Experience Check

Check Dr. Egrie's experience treating your condition or procedure

Dr. Egrie's Top Procedures and Conditions

Treatment Frequency
Mitral Valve Disease
normal
normal

Treatment Frequency

Dr. Egrie treats Mitral Valve Disease more than 69% of his peers

Dr. Egrie treats this condition more than 69% of his peers

Rating Includes other areas of care:

  • Congenital Mitral Stenosis
  • Mitral Valve Stenosis
Heart Disease
normal
normal

Treatment Frequency

Dr. Egrie treats Heart Disease more than 69% of his peers

Dr. Egrie treats this condition more than 69% of his peers

Mitral Valve Surgery
normal
normal

Treatment Frequency

Dr. Egrie performs Mitral Valve Surgery more than 66% of his peers

Dr. Egrie performs this procedure more than 66% of his peers

Rating Includes other areas of care:

  • Mitral Valve Repair
  • Mitral Valve Replacement
  • Transcatheter Mitral Valve Repair
  • Transcatheter Mitral Valve Replacement

Dr. Egrie's conditions and procedures:

Aneurysm
Angina and Acute Coronary Syndrome
Aortic Aneurysm
Aortic Dissection
Aortic Ectasia
Aortic Embolism and Thrombosis
Aortic Repair, Open or Repair of Arterial Aneurysm, Open
Aortic Stenosis
Aortic Valve Disease
Aortic Valve Regurgitation
Aortic Valve Surgery
Arrhythmias
Atrial Fibrillation
Atrial Flutter
Benign Tumor
Cancer
Cardiac Catheterization (incl. Coronary Angiography)
Cardiac Electrophysiology
Cardiac Shunting Procedures With or Without Aortic Repair or Coronary Anomaly Repair
Cardiomegaly
Cardiomyopathy
Cardioverter-Defibrillator or Pacemaker Insertion, Removal or Repair
Carotid Artery Disease
Chest CT (incl. Heart and Lungs)
Congenital Aortic Valve Disorders
Congenital Heart Defects
Congenital Heart Disease
Congestive Heart Failure
Coronary Angioplasty, Atherectomy and Stent
Coronary Artery Bypass Graft (CABG) Surgery
Coronary Artery Disease (CAD)
Coronary Artery Dissection
Decortication and Pleurectomy
Empyema
Endocarditis
Endovascular Repair of Aorta
Esophageal Cancer
Esophageal Diseases
Esophageal Surgery
Esophagectomy (Esophagogastrostomy, Esophagojejunostomy)
Excision of Esophageal Lesion
Head and Neck Cancer
Head and Neck Surgery
Heart Attack (Acute Myocardial Infarction)
Heart Defect Repair
Heart Disease
Heart Surgery
Heart Tumors, Benign
Hernia Repair
Impella Device
Insertion of Epicardial Lead for Pacemaker or Cardioverter and-or Defibrillator
Insertion of Left Ventricular Lead for Pacemaker or Cardioverter and-or Defibrillator
Laparoscopic Surgical Procedure
Lung Cancer
Lung Surgery
Lymph Node Biopsy or Excision
Maze Procedure
Mitral Valve Disease
Mitral Valve Regurgitation
Mitral Valve Stenosis
Mitral Valve Surgery
Pacemaker Insertion or Replacement
Paraesophageal Hernia Repair, Laparoscopic
Patent Ductus Arteriosus
Pericardial Disease
Peripheral Arterial Aneurysm
Peripheral Arterial Aneurysm and Dissection
Peripheral Arterial Dissection
Peripheral Artery Catheterization
Port Placements or Replacements
Pulmonary Disease
Pulmonary Embolism
Pulmonary Valve Disease
Pulmonary Valve Surgery
Removal or Revision of Pacemaker or Cardioverter and-or Defibrillator
Resection of Cardiac Tumor
Rheumatic Aortic Valve Disorders
Ruptured Aortic Aneurysm
Secondary Hypertension
Septal Defect
Thoracentesis
Thoracoscopic Lobectomy
Thoracoscopic Segmentectomy
Thoracoscopic Wedge Resection
Thrombosis
Tracheal Surgery
Tricuspid Valve Surgery
Valve Repair or Replacement (Aortic, Mitral, Tricuspid, and Pulmonary)
Vascular Disease
Vascular Surgical Procedure
Ventricular Assist Device
Video-Assisted Thoracoscopic Surgery (VATS) or Thoracotomy

About Me

Biography

Dr. Glenn Egrie, MD is a cardiac surgery specialist in San Francisco, CA and has been practicing for 23 years. He graduated from Mount Sinai School Of Medicine Of New York University in 1995 and specializes in cardiac surgery.

Specialties

  • Cardiac Surgery

Board Certifications

  • Thoracic Cardiovascular Surgery

Education

  • Ucsf Medical Center
    Fellowship Hospital
  • Massachusetts General Hospital
    Residency Hospital
  • University Of Connecticut Health Center
    Internship Hospital
  • 1995
    Mount Sinai School Of Medicine Of New York University
    Medical School
    1995

Languages

  • Spanish
  • English

Awards

Dr. Egrie's Reviews

Likelihood to recommend Dr. Egrie

5.0

Based on 1 reviews

5 Stars
100%
(1)
4 Stars
0%
(0)
3 Stars
0%
(0)
2 Stars
0%
(0)
1 Star
0%
(0)

Leave a review

How likely are you to recommend
Dr. Egrie?
(Select your rating)
Average Wait Time
  • 31 – 45 minutes
Dr. Egrie's Performance
  • Trustworthiness
  • Explains condition(s) well
  • Answers questions
  • Time well spent
Office & Staff Performance
  • Scheduling
  • Office environment
  • Staff friendliness

Be the first to leave a comment

How was your experience with Dr. Egrie?

Locations

Insurance accepted

Accepted insurance can change. Please double-check when making an appointment.

Aetna
Aetna HMO
Choice Plus POS II
Blue Cross Blue Shield
Blue Card PPO
Blue Cross Blue Shield of California
Blue Cross Blue Shield of California PPO
Select Plus HMO
Cigna
Cigna HMO
Cigna PPO
Open Access Plus
MultiPlan
MultiPlan PPO

Affiliated Hospitals

Check the quality of care at hospitals where Dr. Egrie treats patients.

Learn more

Compare Cardiac Surgeons

More providers who are similar to Dr. Egrie

Show All Cardiac Surgeons